ProPhase Labs, Inc. (Formerly Known as Quigley Corporation)

118 articles about ProPhase Labs, Inc. (Formerly Known as Quigley Corporation)

• ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers

  5/3/2023

  ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its progress and development strategy for Linebacker-1 (LB-1).

• ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1x1 Meetings on Thursday, April 27, 2023

  4/18/2023

  ProPhase Labs, Inc. today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 10:30 am PST, 1:30 pm EST. 

• ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022

  3/28/2023

  ProPhase Labs, Inc. today reported its financial and operational results for the year ended December 31, 2022.

• ProPhase Labs Announces New $6 Million Stock Repurchase Program

  3/15/2023

  ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, announced that its Board of Directors has authorized a stock repurchase program of up to $6 million in ProPhase Labs’ common stock.

• ProPhase Labs’ Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test

  3/7/2023

  ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, Nebula Genomics, Inc. (“Nebula”), has introduced its lowest ever standard price of $249.00 for its direct-to-consumer (DTC) whole genome sequencing (WGS) DNA test.

• ProPhase Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test

  3/1/2023

  ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced a collaboration with mProbe, Inc. (“mProbe”), a precision health and medicine company utilizing clinical proteomics in the oncology space, and Dr. Christopher Hartley of Mayo Clinic for the continued development of its BE-Smart Esophageal Pre-Cancer Diagnostic Screening test.

• ProPhase Labs Announces Plans to Initiate Clinical Trial of Equivir (OTC)

  2/22/2023

  ProPhase Labs, Inc. today announced that its wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), is initiating a randomized, placebo-controlled clinical trial of Equivir (OTC) to evaluate its effect on upper respiratory tract infections.

• ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science

  2/16/2023

  ProPhase Labs, Inc. announced that its flagship diagnostic test, which is undergoing clinical validation as a laboratory developed test for esophageal cancer screening, was featured in International Journal of Molecular Science, volume 24, no. 4 edition.

• ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand

  2/15/2023

  ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, provided a business update with respect to its wholly-owned contract manufacturing subsidiary, Pharmaloz Manufacturing, Inc..

• ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

  2/6/2023

  ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”) today provided an update regarding its progress and development strategy for Linebacker-1 (LB-1), a small molecule PIM kinase inhibitor that is being developed by the Company’s wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), as a potential therapy enhancer for traditional chemotherapeutic agents to both increase efficacy and decrease toxicity in current cancer treatments.

• ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022

  11/30/2022

  ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation.

• ProPhase Labs Announces Record Third Quarter 2022 Financial Results

  11/10/2022

  ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, reported its financial and operational results for the third quarter ended September 30, 2022.

• ProPhase Labs to Present at Investor Summit Group’s Q4 Conference

  11/8/2022

  ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, announced it will be participating in the Q4 Investor Summit Conference, which will take place on November 14, 2022 in New York, New York.

• ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute

  11/8/2022

  ProPhase Labs, Inc. (NASDAQ: PRPH) today announced that its wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), and Dana-Farber Cancer Institute have entered into a two-year collaborative agreement to further the research and development of a small molecule, Linebacker-1 (LB-1), that is intended as a therapy enhancer for traditional chemotherapeutic agents to both increase efficacy and decrease toxicity in current cancer treatments.

• ProPhase Labs Announces Collaboration with G42 Healthcare

  10/19/2022

  ProPhase Labs, Inc. announced today that its wholly-owned subsidiary, ProPhase Precision Medicine Inc., the owner of Nebula Genomics, Inc., has signed a Memorandum Of Understanding (MOU) with G42 Healthcare, a leading Abu Dhabi-based artificial intelligence (AI) health-tech company, to explore several collaborative opportunities including, but not limited to, genomic sequencing, artificial intelligence, sharing of genomic data insights, and obtaining certain advanced certifications.

• ProPhase Labs to Present at The ThinkEquity Conference

  10/18/2022

  ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participating in The ThinkEquity Conference, which will take place on October 26, 2022 at The Mandarin Oriental Hotel in New York, New York.

• Nebula Genomics Strengthens Advisory Board with Appointment of Russ Altman, M.D., Ph.D.

  10/17/2022

  ProPhase Labs, Inc. today announced that its wholly owned subsidiary, Nebula Genomics, Inc., has added Russ B. Altman, M.D., Ph.D to its Advisory Board.

• ProPhase Labs to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

  9/6/2022

  ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022 at 2:30 pm, Eastern Time.

• ProPhase Labs Announces Record Second Quarter 2022 Financial Results

  8/11/2022

  ProPhase Labs, Inc. today reported its financial and operational results for the second quarter ended June 30, 2022.

• ProPhase Labs to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 at 11:00 a.m. Eastern Time

  8/5/2022

  ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, August 11, 2022 at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30,2022.